Vantage Investment Advisors’s AstraZeneca AZN Stock Holding History

Vantage Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$167K	Hold	1,150	–	–	0.04%	166
2018 Q2	$150K	Buy	1,150 +150	+15%	+$10.8K	0.04%	170
2018 Q1	$137K	Sell	1,000 -250	-20%	-$17.3K	0.03%	169
2017 Q4	$139K	Buy	1,250 +1,102	+745%	+$74.3K	0.03%	173
2017 Q3	$10K	Hold	148	–	–	﹤0.01%	559
2017 Q2	$10K	Hold	148	–	–	﹤0.01%	541
2017 Q1	$9K	Hold	148	–	–	﹤0.01%	548
2016 Q4	$8K	Hold	148	–	–	﹤0.01%	546
2016 Q3	$10K	Buy	+148	New	+$9.67K	﹤0.01%	487
2016 Q2	–	Sell	-165	Closed	-$9K	–	839
2016 Q1	$9K	Buy	165 +30	+22%	+$1.8K	﹤0.01%	523
2015 Q4	$9K	Hold	135	–	–	﹤0.01%	515
2015 Q3	$9K	Hold	135	–	–	0.01%	508
2015 Q2	$9K	Sell	135 -165	-55%	-$11.3K	0.01%	494
2015 Q1	$21K	Buy	300 +165	+122%	+$11.5K	0.01%	484
2014 Q4	$10K	Hold	135	–	–	0.01%	496
2014 Q3	$10K	Hold	135	–	–	0.01%	470
2014 Q2	$10K	Hold	135	–	–	0.01%	468
2014 Q1	$9K	Hold	135	–	–	0.01%	438
2013 Q4	$8K	Buy	+135	New	+$7.33K	0.01%	420

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Vantage Investment Advisors's AZN Position: Q3 2018 in Review

Vantage Investment Advisors held its AstraZeneca (AZN) position steady in Q3 2018 at 1,150 shares worth $167K. The position accounts for 0.04% of the portfolio, ranked #166.

Vantage Investment Advisors first reported a position in AZN in Q4 2013 and has held it in 19 quarters since. 544 funds tracked by Wall St. Rank hold AZN as of Q3 2018.

Vantage Investment Advisors held 1,150 shares of AstraZeneca worth $167K as of Q3 2018.
Vantage Investment Advisors left its AstraZeneca share count unchanged in Q3 2018.
AstraZeneca made up 0.04% of Vantage Investment Advisors's portfolio in Q3 2018, its #166 holding.
Vantage Investment Advisors first reported a position in AstraZeneca in Q4 2013 and has held it in 19 quarters since.
544 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.